Adenocarcinoma

91 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Adenocarcinoma
Treatment and conditionWhere it standsTrials
5-FU, Leucovorin, Oxaliplatin, Docetaxel for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apatinib+Camrelizumab+SOX + Preoperative Radiotherapy for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BHB810 for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Histotripsy + DURVALUMAB for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for adenocarcinoma, papillaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for eccrine porocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN + OMEGA-3-ACID ETHYL ESTERS for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Breast Radiotherapy for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib + NIVOLUMAB for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carbon ion irradiation for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CEMIPLIMAB + Gemcitabine + MOTIXAFORTIDE + NAB-PACLITAXEL for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Community Treatment for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Core Biopsy + Questionnaire Administration + AFIMOXIFENE for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
cryoablation + TQB2868 Injection + Catequentinib for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + Gem/Cis for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELI-002 2P for cholangiocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide + Mevrometostat for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
FAPi-46 GA-68 for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Farletuzumab ecteribulin for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GALLIUM GA-68 GOZETOTIDE for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Haic+tae + tislelizumab + surufatinib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan liposomes + ADEBRELIMAB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ivosidenib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivosidenib + Capecitabine + Zanidatamab + Capecitabine + FUTIBATINIB for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Pharmacological Study + BEVACIZUMAB + ATEZOLIZUMAB for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib + farletuzumab ecteribulin for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, acinar cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, serousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, acinar cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, serousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Positron Emission Tomography + PSMA PET Scan + Pemetrexed Disodium + PEMBROLIZUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mitomycin for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nutritional Assessment + Short-Term Fasting + Metformin hydrochloride for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxcel Q3W for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PD-1antibody plus GEMOX for klatskin tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed + Carboplatin + PEMBROLIZUMAB + CISPLATIN for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prostate Radiotherapy + Radical Prostatectomy for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pulmonary segmentectomy for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy + OXALIPLATIN + DOCETAXEL + LEVOLEUCOVORIN + PEMBROLIZUMAB + Fluorouracil for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Segmentectomy for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selpercatinib for carcinoma, medullaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sequential cytoreductive intervention for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SOC plus trastuzumab and pembrolizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonesitatug Vedotin for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonesitatug Vedotin + Rilvegostomig for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sotorasib for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + Bemarituzumab for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + DEPATUXIZUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + NIVOLUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + RAMUCIRUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + TRASTUZUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tamoxifen for carcinoma, intraductal, noninfiltratingPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tarlatamab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Tislelizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
vitamin D 25(OH)D for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for adenocarcinoma, clear cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zolbetuximab for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1